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ABSTRACT
To investigate the influence of the pyrimidine 2-keto
group on selection of nucleotides for incorporation
into DNA by polymerases, we have prepared two C
nucleoside triphosphates that are analogues of dCTP
and dTTP, namely 2-amino-5-(2′-deoxy-β-D-ribofurano-
syl)pyridine-5′-triphosphate (d*CTP) and 5-(2′-deoxy-
β-D-ribofuranosyl)-3-methyl-2-pyridone-5′-triphosphate
(d*TTP) respectively. Both proved strongly inhibitory
to PCR catalysed by Taq polymerase; d*TTP rather
more so than d*CTP. In primer extension experiments
conducted with either Taq polymerase or the Klenow
fragment of Escherichia coli DNA polymerase I, both
nucleotides failed to substitute for their natural pyrimi-
dine counterparts. Neither derivative was incorporated
as a chain terminator. Their capacity to inhibit DNA
polymerase activity may well result from incompatibility
with the correctly folded form of the polymerase
enzyme needed to stabilize the transition state and
catalyse phosphodiester bond formation.
INTRODUCTION
DNA replication is dependent on faithful copying of DNA by
polymerases (1). Structural studies have indicated that the
majority of polymerases belong to an enzyme superfamily having
closely related active sites similarly positioned within a polymer-
ase cleft (2–3). Steitz (4) has pointed out that specific recognition
and positioning of the O2 atoms of pyrimidines and the N3 atoms
of purines by protein side chains may be important to the
mechanism by which polymerases enhance the fidelity of
Watson–Crick base pairing and promote correct nucleotide
incorporation at the active site. A similar conclusion was reached
by Georgiadis et al. (5), arising from a detailed modelling study
with reverse transcriptase.
DNA polymerases can sometimes tolerate chemical changes in
their nucleotide substrates and in previous work we have used
PCR with Taq DNA polymerase to incorporate nucleotide
analogues with added/deleted functional groups into DNA (6–8).
Analogue triphosphates, such as d(2,6-diaminopurine)triphos-
phate instead of dATP (addition of the 2-amino group) and dITP
in place of dGTP (deletion of the 2-amino group), as well as a
wide variety of pyrimidine nucleotides modified at the 5 position,
have been enzymatically incorporated into DNA sequences
(Guo,M.J.and Waring,M.J. unpublished results). An opportunity
therefore arises to determine whether pyrimidine nucleotide
analogues modified at the O2 carbonyl can serve as substrates for
DNA polymerases or not and thereby to put the specific
predictions of the crystallographic and modelling studies (4,5) to
the test.
In order to probe functional group interactions involving the O2
carbonyl of thymidine and deoxycytidine we first set out to
prepare pyrimidine-like nucleoside triphosphate derivatives of
dT and dC from which the O2 carbonyls had been selectively
deleted without otherwise altering hydrogen bonding characteris-
tics. Such derivatives should permit normal dA-dT (or dG-
dC)-like Watson–Crick hydrogen bonding between the incoming
triphosphate analogue and the corresponding template purine
residue. We initially prepared a 4-pyrimidinone derivative to
serve as a dT analogue (9), but elimination of the O2 carbonyl
from the pyrimidine nucleobase resulted in a tautomeric change
at the N3 nitrogen such that a hydrogen bond donor was converted
to a hydrogen bond acceptor. Incorporation of this derivative into
DNA sequences (paired with dA) resulted in destabilized
duplexes (Lan,T. and McLaughlin,L.W., unpublished results),
presumably due to apposition of the electron lone pairs of the N1
of dA and the N3 of the 4-pyrimidinone derivative. Similar
concerns arise with the pyrimidine analogue of dC, in which the
exocyclic amino group most likely exists in the imino tautomer.
To eliminate these undesirable tautomers from the analogue
triphosphates we designed C nucleosides based upon 2-pyridone
and 2-aminopyridine ring systems (10). 2-Hydroxypyridine
heterocycles generally prefer the keto or 2-pyridone tautomer and
as such a 2-pyridone nucleoside should function as a bidentate
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hydrogen bond donor/acceptor and base pair with a complemen-
tary dA in much the same manner as does the native thymine
derivative. Similarly, the 2-aminopyridine nucleoside should
prefer the amino tautomer and engage in two complementary
hydrogen bonds to a template dG residue. According to this
reasoning the best analogues to test for acceptability to polymer-
ases would be 5-(2′-deoxy-β-D-ribofuranosyl)-3-methyl-2-pyri-
done-5′-triphosphate (d*TTP) (3) and 2-amino-5-(2′-deoxy-
β-D-ribofuranosyl)pyridine-5′-triphosphate (d*CTP) (8). Here
we report our results on synthesis of these compounds and their
ability to function with DNA polymerases.
A secondary goal of the present work was to construct by PCR
a series of tyrT DNA molecules containing pyrimidines lacking
the O2 substituent in order to investigate the role of the third
(minor groove) hydrogen bond in G·C and diaminopurine·T base
pairs as a potential determinant of sequence-specific recognition
by ligands. Previous studies (11–14) have furnished abundant
evidence of the importance of the purine 2-amino group as
regards ligand binding, but have left open the question whether
the influence of that group depends upon its forming a minor
groove Watson–Crick hydrogen bond to the O2 of the comple-
mentary pyrimidine or not. Studies involving incorporation of the
two novel bases from d*TTP and d*CTP, together with dA or
dDAP and dG or dI in the other strand (8), should provide a
definitive answer to the question.
MATERIALS AND METHODS
Chemicals and biochemicals
Ammonium persulphate, Tris base, acrylamide, bis-acrylamide,
ultrapure urea, boric acid and tetramethylethylenediamine were
from BDH. Photographic requisites were from Fuji. Bromo-
phenol blue and xylene cyanol were from Sigma. [γ-32P]ATP
(6000 Ci/mmol) was obtained from Amersham International. The
natural nucleotides dGTP, dATP, dCTP and dTTP were purchased
from Pharmacia. Restriction endonuclease EcoRI, Taq polymerase
(Promega) and T4 polynucleotide kinase (Pharmacia) were used
according to the supplier’s recommended protocols in the activity
buffer provided. Synthetic oligonucleotides were obtained from
the Protein and Nucleic Acid Chemistry Facility Laboratory in
the Department of Biochemistry, Cambridge University. All other
chemicals were analytical grade reagents and all solutions were
prepared using doubly deionized Millipore filtered water. 1H and
31P NMR spectra were obtained on a Bruker DRX
300 spectrometer. 31P NMR spectra were referenced to phosphoric
acid.
Synthesis of nucleotide analogues
Analytical HPLC was performed on a 50 × 7.8 mm BioRad
HRLC MA7Q anion exchange column, running a linear
gradient of 100% A (0% B) to 50% A (50% B) over 8 min at a
flow rate of 4 ml/min, which provides an increase in ammonium
bicarbonate concentration from 50 to 375 mM. Semi-preparative
HPLC was performed on a Hichrom Partisil 10 SAX anion
exchange column running a gradient of 100% C (0% D) to 10%
C (90% D) over 18 min at a flow rate of 7 ml/min, providing a
linear increase in KH2PO4 concentration from 50 to 635 mM.
(Buffers: A, 50 mM ammonium bicarbonate; B, 0.7 M ammon-
ium bicarbonate; C, 50 mM potassium dihydrogen phosphate,
pH 7.0; D, 0.7 M potassium dihydrogen phosphate, pH 7.0.)
The buffer phosphate was removed by running the solution
through a DEAE-Sephadex A-25 anion exchange column,
washing with 100 mM triethylammonium bicarbonate (TEAB)
and then eluting with 400 mM TEAB. The fractions containing
product were pooled together, evaporated to dryness and
converted into the sodium salt by dissolving in water and passing
through a column of sodium Dowex 50 X 2 ion exchange resin.
Tetra-n-butylammonium pyrophosphate (15,16). Tetrasodium
pyrophosphate decahydrate (13.4 g, 30 mmol) was converted to
its pyridinium salt by dissolving it in water and passing through
a column of pyridinium Dowex 50 X 2 ion exchange resin (100g,
200–400 mesh). The salt was eluted with five times the column
volume of deionized water. The eluate was evaporated to dryness
under reduced pressure. After dissolving the residue in dry
pyridine, 26.4 ml (120 mmol) tri-n-butylamine were added and
the resulting liquid was shaken until a clear solution resulted.
Solvent was then removed under reduced pressure. The residue
was co-evaporated with dry pyridine three times, dissolved in dry
DMF and adjusted to a final volume of 60 ml of a 0.5 M solution.
This solution is stable for at least two months when stored at 4C.
General procedure for phosphorylation (17–19). The requisite
nucleoside (0.5 mmol) and 1,8-bis(dimethylamino)naphthalene
(Proton Sponge) (0.75 mmol, 1.5 equiv.) were dissolved in 3 ml
trimethylphosphate (dried with 4A molecular sieves) and cooled
to –20C before phosphorus oxychloride (1.5–2 equiv.) was
pipetted into the solution (suspension). The mixture was stirred
with cooling for 3 h and the temperature was kept between –10
and –20C. Aliquots of 5 ml 0.5 M pyrophosphate solution (in
DMF, 5 equiv.) were added, followed by 0.5 ml tri-n-butylamine.
The mixture was again stirred with cooling for 3 min. TEAB (30
ml, 0.4 M) was added and stirring continued at room temperature
for 10 min. Volatiles were removed under reduced pressure and
to the residue was added 30 ml diethyl ether. Liquid was removed
by desiccation and the solid residue was washed with 30 ml
diethyl ether. It was then dissolved in 20 ml water and loaded onto
a DEAE-Sephadex A-25 anion exchange column (3 × 25 cm) for
separation. Elution was conducted from 2L 0.1 M to 2L 0.7 M
TEAB; the product eluted from the column near 0.35 M TEAB.
Appropriate fractions were collected and volatiles removed under
reduced pressure. The product was converted into the sodium salt
by passing through a Dowex 50 X 2 ion exchange column (in the
sodium form).
5-(2′-Deoxy-β-D-ribofuranosyl-3-methyl-2-pyridone-5′-triphos-
phate (3) (d*TTP) (Fig. 1). Phosphorylation of 57.2 mg (0.19 mmol)
2-benzyloxy-5-(2′-deoxy-β-D-ribofuranosyl)-3-methylpyridine (1)
(10) with 60 mg Proton Sponge, 2 ml trimethyl phosphate, 35 µl
phosphorus oxychloride, 2 ml 0.5 M tetra-n-butylammonium
pyrophosphate and 0.2 ml tri-n-butylamine yielded 70 mg
2-benzyloxy-5-(2′-deoxy-β-D-ribofuranosyl)-3-methyl-pyridine-
5′-triphosphate (2) as its sodium salt after column separation. This
product was then dissolved in 10 ml water/ethanol (1:1 v/v), 5 mg
10% Pd/C was added and the mixture was stirred under a hydrogen
atmosphere for 7.5 h. After removing catalyst and solvent the residue
was purified by HPLC [retention time (RT) 9.8 min], resulting in
28.3 mg 5-(2′-deoxy-β-D-ribofuranosyl)-3-methyl-2-pyridone-
5′-triphosphate (3). 1H NMR in D2O δ (p.p.m.): 7.56 (s, 1H, H6),
7.42 (s, 1H, H4), 4.92 (t, 1H, H1′), 4.48 (bs, 1H, H3′), 4.08 (bs,
1H, H4′), 4.02 (m, 2H, H5′), 2.08 (m, 2H, H2′), 2.0 (s, 3H, CH3).
31P NMR in D2O δ (p.p.m.): –6.5 (m), –11.1 (m), –21.9 (m).
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Figure 1. Reaction scheme for synthesis of d*TTP (3).
2-Amino-5-(2′-deoxy-β-D-ribofuranosyl)pyridine-5′-triphosphate
(8) (d*CTP) (Fig. 2). A solution of 2-(benzoylamino)-5-
(2′-deoxy-β-D-ribofuranosyl)pyridine (4) (130 mg, 0.41 mmol)
(20) in 15 ml 40% methylamine was heated at 70C for 26 h. The
mixture was concentrated in vacuo and the residue dissolved in
30 ml dry methanol, 3 ml N,N-dimethylformamide dimethyl-
acetal were added and the solution was refluxed overnight. After
removing solvent the residue was purified on a silica gel column
with 5–10% methanol in chloroform as eluent. This gave 77 mg
(0.29 mmol) 2-(N,N-dimethylamidinyl)-5-(2′-deoxy-β-D-ribo-
furanosyl)pyridine (6). The product was phosphorylated with
90 mg Proton Sponge, 3 ml trimethyl phosphate, 53 µl phos-
phorus oxychloride, 3 ml 0.5 M tetra-n-butylammonium
pyrophosphate and 0.3 ml tri-n-butylamine. The reaction mixture
was separated on a DEAE-Sephadex column using the conditions
described before, appropriate fractions were collected and
volatiles were removed under reduced pressure. The residue
[2-(N,N-dimethylamidinyl)-5-(2′-deoxy-β-D-ribofuranosyl)-
pyridine-5′-triphosphate (7)] was suspended in 20 ml concentrated
ammonia and heated at 50C for 4 h. Insoluble material was
removed by filtration and the filtrate was concentrated under
reduced pressure. The residue was further purified by semi-
preparative anion exchange HPLC (RT 9.8 min), resulting in
17.5 mg 2-amino-5-(2′-deoxy-β-D-ribofuranosyl)pyridine-5′-tri-
phosphate (8) as its sodium salt. 1H NMR in D2O δ (p.p.m.): 8.99
(s, 0.5 H, not fully exchanged NH2), 8.28 (bs, 1H, H6), 7.91 (dd, 1H,
H4), 7.81 (d, 0.5H, H3, J = 8.6 Hz), 7.03 (d, 0.5H, H3, J = 8.3 Hz),
5.22 (dd, 1H, H1′, J = 5.1 Hz, J = 11 Hz), 4.87 (dd, 1H, H3′, J =
6.7 Hz, J = 6.9 Hz), 4.44 (bs, 1H, H4′), 3.81 (m, 2H, H5′), 2.51
(dd, 1H, J = 5.3 Hz, J = 14 Hz, H2a′), 2.15 (m, 1H, H2b′). 31P
NMR in D2O δ (p.p.m.): –6.4 (d), –12.8 (d), –21.9 (m)
Primer 5′-labelling and purification
A Watson primer representing the first 20 nt of the top strand of
tyrT DNA (21) having the sequence 5′-GTT ACC TTT AAT
CCG TTA CG-3′ was 5′-end-labelled with [γ-32P]ATP in the
presence of T4 polynucleotide kinase according to a standard
procedure (22). Thus, a 200 µl solution containing 4 µl 5.3 mM
Watson primer, 167 µl TN buffer, 20 µl 10× T4 polynucleotide
kinase buffer, 5 µl [γ-32P]ATP (6000 Ci/mmol) and 4 µl T4
polynucleotide kinase was incubated for 40 min at 37C and then
heated at 70C for 10 min. Loading dye (20 µl) was added and
the solution was loaded onto a 10% polyacrylamide gel running
at 270 V for 1.5 h. The labelled primer band was cut out and
electroeluted into 10 M ammonium acetate solution at 140 V for
40 min. The labelled primer was precipitated from the ammonium
acetate solution by adding 3 volumes of absolute ethanol and was
further desalted by repeated ethanol precipitation. The primer was
finally dissolved in 1 ml TN buffer to give a 5.8 µM solution,
according to UV measurements.
Figure 2. Reaction scheme for synthesis of d*CTP (8).
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PCR protocol
In general the procedure used for PCR experiments was adapted
from the standard protocol described previously (23,24). Reaction
mixtures (50 µl) contained 10 ng tyrT(A93) template (the
EcoRI–AvaI fragment) (5), 1 µM each primer [top (Watson)
strand primer 5′-end labelled by prior incubation with [γ-32P]ATP
and polynucleotide kinase; bottom (Crick) strand primer 5′-GGG
CTC GGG AAC CCC CAC CA-3′], 250 µM each natural
nucleoside triphosphate, varying concentrations of either d*CTP
or d*TTP as stated and 1 U Taq DNA polymerase. The PCR
reactions were buffered with the commercially supplied solutions
to final conditions of 50 mM KCl, 10 mM Tris–HCl, pH 9.0,
1.5 mM MgCl2 and 0.1% Triton X-100. In order to prevent
non-specific primer annealing the reaction mixtures were heated
to 60C prior to addition of the appropriate DNA polymerase. To
each tube ∼50 µl mineral oil was then added to prevent
evaporation. The samples were heated to 94C for 3 min.
Following this initial denaturation step 20 amplification cycles
were performed consisting of 94C denaturation for 1 min, a
37C primer annealing step for 2 min and a 72C polymerization
step for 10 min. After completion of the last amplification cycle
the samples were heated to 72C for another 10 min to complete
unfinished chains, following which the reactions were cooled
slowly to allow efficient annealing of complementary DNA
strands. Two additional 5 min steps were included, one at 55 and
one at 37C. After the entire process was complete the mineral oil
was removed by extracting with chloroform, 5 µl of loading dye
were added to each sample and 8 µl were then loaded onto a 6%
non-denaturing polyacrylamide gel to analyse the products.
Primer extension experiments
To investigate whether d*CTP and d*TTP would serve as
substrates for particular DNA polymerases or not two templates,
a 25mer having the sequence 5′-T CAG TCG TAA CGG ATT
AAA GGT AAC-3′ and a 24mer with the sequence 5′-CGA CCG
TAA CGG ATT AAA GGT AAC-3′ were used. The difference
between these two templates lies only in the bases extending
beyond the region complementary to the primer (the 25mer
contains all four bases, while the 24mer lacks T and therefore will
not direct incorporation of dA into the product). The complemen-
tary 20 nt Watson primer was labelled with 32P at its 5′-end as
described above.
Aliquots of 0.5 µM each appropriate template, primer, 100 µM
each natural nucleoside triphosphate and 1 U DNA polymerase
were used in a 50 µl reaction mixture buffered with the
commercially supplied solutions. In order to prevent non-specific
primer annealing all reactions were heated to 80C for 5 min and
then cooled to ambient temperature prior to addition of the
appropriate DNA polymerase. Mixtures were incubated at 37C
overnight, then 5 µl loading dye were added to each sample and
8 µl were loaded onto a 20% denaturing polyacrylamide gel to
analyse the results.
Gel electrophoresis and autoradiography
For primer extension reactions the products were analysed by
PAGE under denaturing conditions (0.3 mm, 20% acrylamide
gels containing 7 M urea and TBE). Electrophoresis was carried
out at 60 W in 1× TBE buffer for ∼4 h. After electrophoresis was
complete the gel was fixed in 10% (v/v) acetic acid containing
10% methanol (v/v) for 15 min. For PCR reactions the products
were analysed on polyacrylamide gels under non-denaturing
conditions (0.3 mm, 6% acrylamide). Electrophoresis was carried
out at 900 V in 1× TBE buffer for ∼2 h. The gel was then
transferred to Whatman 3MM paper, dried on a gel drier under
vacuum at 80C and exposed to a PhosphorImager screen and/or
an X-ray film (Fuji R-X) for ∼48 h.
Quantification by storage phosphorimaging
A Molecular Dynamics 425E PhosphorImager was used to
collect data from the storage screens exposed to dried gels
overnight at room temperature (25). Baseline-corrected scans
were analysed by integrating all the densities between two
selected boundaries using ImageQuant v.3.3 software.
RESULTS
Chemical syntheses
In the initial synthesis of the 2′-deoxycytidine analogue 4 a
benzoyl group was used to protect the 2-amino substituent, which
could be removed with either 40% methylamine at 70C for 25 h
(20) or concentrated ammonia at 60C for 3 days (10).
Unfortunately, under these conditions the triphosphate will be
destroyed. Therefore, a new protecting group for the exocyclic
amino substituent had to be sought. We used anion exchange
HPLC to examine the stability of dNTPs under varying reaction
conditions. In 40% methylamine at 70C 40% of the dNTP
decomposed after 1 h, 70% after 5 h and >95% had been lost after
17 h, but at ambient temperature with potassium carbonate in
methanol/water (5:1), 40% methylamine, and 0.5 M TEAB
solutions dNTPs were stable for >24 h. In concentrated ammonia
at ambient temperature dNTPs are stable for long periods of time,
but at 50C 25% decomposition was observed after 17 h. The
dNTPs treated for 1 h in 2 M TEAB were completely hydrolysed
and 50% was lost after 4 h in 1 M TEAB. With 10% Pd/C in
ethanol and 8 h at ambient temperature about one third
decomposed. We tried trifluoroacetyl as an amine protecting
group but were unable to remove it from the 3′,5′ positions
selectively. Eventually we chose an amidine (Me2NCH=) to
protect the exocyclic amino group (26), as it can be incorporated
easily under mild conditions and readily removed by concen-
trated ammonia at 50C. After deprotection and separation of the
dNTP product by DEAE-Sephadex column chromatography the
phosphorylated product contained a small amount of an unidenti-
fied by-product which was removed by HPLC purification using
an anion exchange column.
We note that the pKa of d*C is 6.26, compared with 4.3 for
natural 2′-deoxycytidine (20), so that at pH 7 d*CTP exists in two
forms (protonated and unprotonated) in approximately equal
proportions, as revealed by NMR analyses of the protons on the
base, which appear as two sets of signals at different positions in
the 1H NMR spectrum.
PCR
Initial experiments quickly revealed that substituting d*CTP for
dCTP or d*TTP for dTTP in the PCR amplification procedure
under standard conditions using Taq polymerase failed to yield
detectable amounts of full-length product. Other conditions were
explored and the concentration of each analogue was varied over
a wide range in separate experiments, but little or no PCR product
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Figure 3. Formation of PCR products in the presence of d*CTP (lanes 3–10)
or d*TTP (lanes 14–21). Lanes 1, 11, 12 and 22 contained the primer alone.
Lanes 2 and 13 show the results of the control PCR without any nucleotide
analogue added.
was obtained. Other heat-stable enzymes were also tested, but to
no avail. Suspecting that the compounds might be inhibitory to
polymerase activity, they were then added to standard reaction
mixtures (containing all four natural nucleoside triphosphates at
250 µM each) and both analogue dNTPs were found to cause
progressive concentration-dependent suppression of full-length
product synthesis without accumulation of any discrete bands
corresponding to truncated chains (Fig. 3). The d*TTP derivative
proved to be a more powerful inhibitor than d*CTP, causing 50%
inhibition at ∼20 µM, while the same extent of inhibition by the
cytidine derivative required a slightly higher concentration of
40 µM (Fig. 4). Given the pKa of the deoxycytidine analogue
(6.26), this factor of two difference in inhibitory concentrations
may simply reflect the available concentration of the unproto-
nated form of d*CTP.
Primer extension reactions
The observed inhibition of polymerase activity might result from
simple competition between analogues and natural substrates for
the active site, from analogue incorporation in the fashion of a
chain terminator, or from some non-specific inhibitory action on
the polymerase–template–primer complex with or without tem-
plate-directed false nucleotide incorporation. To distinguish
between these various possibilities we designed two template
sequences, each complementary to the same primer used in the
PCR experiments but carrying a 4 or 5 nt 5′-overhang, so as to
permit extension of the primer by polymerase action. The results
of an experiment with d*TTP and Taq polymerase are shown in
Figure 5. The first thing to note is that the product in each control
lane (no d*TTP added) consists of two bands, of which the
stronger is 1 nt longer than the predicted product strictly
complementary to the template overhang. This addition of an
‘extra’ nucleotide is a peculiarity observed with several polymer-
ases under artificial conditions involving long incubation times,
often exacerbated when dATP is present (27). Interestingly, the
presence of d*TTP tends to suppress addition of this ‘extra’
nucleotide such that the predominant product corresponds to
Figure 4. Inhibition of the PCR reaction by d*CTP () and d*TTP (∆). The
ordinate shows the fractional conversion of added primer to full-length PCR
product.
Figure 5. Failure of d*TTP to substitute for dTTP in the primer extension
reaction with Taq polymerase. The position of the primer band is shown in the
lane at the extreme left; the direction of migration was from the top to the
bottom. The 25mer template was used. Each set of three lanes shows the
products resulting from incubation with the natural nucleotides indicated in the
box below them, with d*TTP added as indicated above. The bands correspon-
ding to products with 1–5 nt added are identified at the left.
correct template-directed incorporation of the natural nucleotides
present. Evidently there is no significant inhibition of the normal
extension reaction under these conditions, though the rate of
nucleotide addition may be slowed considerably. Equally evidently,
d*TTP cannot substitute for dTTP, because whenever d*TTP is
added and dTTP is omitted the length of the product corresponds
to one terminated immediately before the T incorporation step,
i.e. with A and C incorporated plus, sometimes, an ‘extra’
nucleotide. There is absolutely no sign of an increase in the length
of any product when reactions containing 30 or 100 µM d*TTP
are compared with control reactions lacking the analogue, as
would be the case if d*TMP had been incorporated and then
served as a chain terminator. Similar results were obtained in
parallel experiments with d*CTP (data not shown).
Taq polymerase is characterized by low stringency as regards
incorporation of unnatural nucleotides, so the experiments were
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Figure 6. Failure of d*CTP to substitute for dCTP in the primer extension
reaction with the Klenow fragment of DNA polymerase. Details of the
experiment as described in the legend to Figure 5.
repeated with the Klenow fragment of E.coli DNA polymerase I
(Fig. 6). Again, in the control reactions (no d*CTP) some
incorporation of an ‘extra’ nucleotide at the ends of truncated
products is evident, though generally not nearly so marked as was
observed with Taq polymerase, and the magnitude of the effect is
more or less proportional to the number of substrate nucleotides
present. This suggests that the ‘extra’ nucleotide may arise at least
partially from trace contamination of one nucleoside triphosphate
with another, though it remains entirely possible that it is simply
nucleotide misincorporation, which might occur over prolonged
periods, particularly at a lower than optimum temperature that
might alter fidelity. Nevertheless, the phenomena noted with Taq
polymerase are largely confirmed: there is now substantial
inhibition of normal chain extension by 200 µM d*CTP, but in no
case is there evidence of the analogue substituting for dCTP or
leading to formation of a product longer than that seen in the
corresponding reaction performed without d*CTP. Similar results
were obtained in parallel experiments with d*TTP (data not
shown).
In an effort to alleviate any ambiguity arising from ‘extra’
nucleotide incorporation by Taq polymerase the primer extension
experiment was redesigned with a slightly shorter template
having a 4 nt overhang devoid of thymine residues, so that dATP
could be omitted from the reaction mixture (Fig. 7). In this
experiment a much weaker ‘extra’ band or bands appeared in
control reactions, fully consistent with slight contamination
between nucleotides, and the effects of d*CTP and d*TTP were
unchanged: there was little or no inhibition of formation of the
expected product (though consistent suppression of ‘extra’
bands) and each analogue completely failed to substitute for the
natural nucleotide in the primer extension reaction.
DISCUSSION
In comparing the d*CTP and d*TTP analogues with the natural
dCTP and dTTP nucleotides there are two major differences.
First, the normal C-N glycosidic bond has been changed to a C-C
bond, which, being slightly longer, may alter the conformation
around the ribose ring due to different steric and electronic
interactions between segments of the nucleotides and polymer-
ases. Benner and colleagues (28) have demonstrated that this kind
of modification is accepted by T7 RNA polymerase using a C-C
ribonucleotide analogue, and a variety of C nucleoside com-
Figure 7. Failure of nucleoside triphosphate analogues to serve as substrates for
Taq polymerase in the primer extension reaction with a 24mer template. Details
of the experiment as for Figure 5.
pounds (including several antibiotics) have long been known
whose biological properties may include facile phosphorylation
to the triphosphate level leading to extensive incorporation into
nucleic acids in vivo (29). So the altered glycosidic bond seems
unlikely to be responsible for the observed inhibitory effects. The
second modification in the analogues is deletion of the 2-keto
group from the pyrimidine ring. It is known that both hydrogen
bond acceptors, the O2 atoms of pyrimidines and the N3 atoms
of purines, lie in overlapping positions in the minor groove for all
four base pairs (4) and these functional groups are invariant
within normal sequences but can be differently positioned for
non-Watson–Crick base pairs. Recently Steitz and colleagues
have published a crystal structure of Taq polymerase containing
DNA at the active site (4). They compared the structure of the
duplex DNA in the complex with those of A- and B-form DNA
and showed that it displays characteristics of both A and B forms,
but is not identical to either. The minor groove is wider than that
of B-form DNA and is accessible to protein side chains that can
hydrogen bond to the O2 atoms of pyrimidines and N3 atoms of
purines. They note that specific recognition and positioning of
these base hydrogen bond acceptors by protein side chains may
be an important mechanism by which polymerases enhance the
fidelity of Watson–Crick base pairing and ensure correct
nucleotide incorporation at the polymerase active site.
Our results show that pyrimidine nucleotides lacking the 2-keto
group are not substrates for the polymerases tested and, indeed,
inhibit activity of the enzymes. This observation is entirely
consistent with the view of Eom et al. (4) and Georgiadis et al. (5)
that the 2-keto group is vital for polymerase recognition. The
crystallographic and modelling studies of these authors led in
each case to the observation of a close contact between the O2
carbonyl and an amino acid side chain which strongly suggests a
critical contact, but in the absence of studies of function cannot
confirm it. The present work provides the necessary functional
study, indicating that such a contact is indeed important for
polymerase activity. It is possible that the 2-keto group may assist
the polymerase to adopt a properly folded form, by forming a
hydrogen bond(s) with the protein side chain(s) and bringing
appropriate functional groups into the correct positions in the
active site to catalyse formation of a new internucleotide bond and
facilitate release of inorganic pyrophosphate from the complex.
The inhibitory activity of these analogues would then be the result
of the absence of a necessary conformational change and/or
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improper folding at the active site caused by the presence of
nucleotides lacking the 2-keto group. The unnatural triphosphate
will bind in what amounts to the ‘right’ place but block formation
of the activated state and prevent elongation of the chain.
Recently Moran et al. (30) have incorporated a difluorotoluene
nucleoside into DNA by solid phase synthesis and used it as a
template for DNA polymerase extension. They noted that this
analogue can be copied as if it were thymidine. On this evidence
they suggested that the shape of the DNA base may be the chief
property by which DNA replicating enzymes select the correct
nucleosides to insert into a growing strand, and shape might be
more important than hydrogen bonding in explaining the extreme
accuracy by which DNA polymerases copy DNA. In another
paper (31) Kool and co-workers have demonstrated that the
difluorotoluene nucleoside triphosphate (dFTP) is a substrate for
Klenow fragment polymerase. dFMP was incorporated into
newly synthesized DNA opposite A in the template. Again, it was
argued that shape complementarity is likely to be the most
important criterion and hydrogen bonds might even be eliminated
if the steric requirements are met. However, a more recent paper
by Evans and Seddon (32) provides evidence that 2,4-difluoro-
toluene can act as a hydrogen bond donor and acceptor, which
contradicts the hypothesis of Kool et al. and would tend to support
the conclusions of the present paper in terms of the relevance of
hydrogen bonding to fidelity. Calculations (33) and measurement
(34) reveal that although the hydrogen bonding ability of
difluorotoluene in chloroform is small, it remains difficult to
predict that ability in a protein environment such as the active site
of a polymerase. Based on our results presented here, together
with a wider examination of pyrimidine analogues as polymerase
substrates, it appears that the right hydrogen bonding properties
are important both for a compound to serve as a substrate for
DNA polymerase and the speed with which the enzyme can use
it to extend the growing chain. Even if the canonical Watson–
Crick hydrogen bonds are not absolutely required for high fidelity
of replication, the ability to engage in some kind of hydrogen
bonding between the polymerase and the groups at position 2 (for
pyrimidine) or 3 (for purine) appears vital. It remains to be
determined whether other pyrimidine analogues with altered
hydrogen bonding capability at position 2 are acceptable as
polymerase substrates, such as variants of d*CTP and d*TTP
with fluorine at the 2 position. The present analogues might also
be useful in crystallographic studies of the polymerase active site
if crystals of complexes can be grown. Sadly, the goal of
investigating the importance of the third (minor groove)
hydrogen bond in a G-C or DAP-T base pair for ligand binding
interactions must be addressed in some other way. There are
indications that if the 2-keto function of cytosine is lost the
2-amino group of guanine may also need to be eliminated in order
to form a stable base pair of the Watson–Crick type (35).
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